Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | V278fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM V278fs results in a change in the amino acid sequence of the Atm protein beginning at aa 278 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). V278fs has not been characterized, however, due to the effects of other truncation mutations downstream of V278 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM V278fs |
Transcript | NM_000051.4 |
gDNA | chr11:g.(108244956_108244957) |
cDNA | c.(832_831) |
Protein | p.V278fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005271562 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017790 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_006718843 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542840 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017791 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_005271561 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542843 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017792.2 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_047426981.1 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017792 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
XM_017017789 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
NM_000051 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.(108244956_108244957) | c.(832_831) | p.V278fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|